List of Imaging Companies in United Kingdom - 8

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics’ expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

We turn ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. Impactful. Scalable. Smart. Brainomix 360 enhances stroke imaging interpretation for neurologists, interventionalists, and radiologists while seamlessly fitting into existing radiology workflows. Delivering the right insights, to the right people, at the right time. Since our 2010 spin-out from the University of Oxford, we've developed award-winning, AI-powered imaging biomarkers and software solutions that empower physicians worldwide to make critical, life-saving decisions in stroke and lung care.

Cirdan designs, manufactures and supplies innovative software and imaging solutions for the acceleration and enhancement of diagnosis. Our systems are optimised for pathology and clinical laboratory usage. Cirdan's primary product is its world-class Laboratory Information System, ULTRA. ULTRA has been designed to streamline laboratory operations and is currently installed in more than 72 laboratories across 6 continents. Another core product is PathLite Compact, a purpose-built system designed specifically for gross imaging within clinical laboratories. The company was founded in 2010 and is headquartered in Lisburn, Northern Ireland and has additional offices in Canada and Australia. Cirdan is also responsible for organising Pathology Horizons, an annual and open CPD conference on the future of pathology. For more information visit - www.pathologyhorizons.com

Advancing medicine and human health by transforming data into clinically meaningful insights. IXICO is a premier neuroimaging provider helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights. Bringing together world-class therapeutic expertise, breakthrough analytics and operational excellence, IXICO is the proven partner of choice for imaging biomarker solutions in CNS clinical trials.

We’re here to accelerate your therapy’s journey through the complexities of drug discovery and development. Putting innovation at the forefront of our capabilities, industry-leading experts help you confidently and proactively answer critical questions around the safety and efficacy of your product with our gold-standard in vitro models. By harnessing the power of predictive data, we navigate this crucial step efficiently and cost-effectively to maximise the potential of your therapy achieving clinical and market success. By combining our unique expertise with cutting-edge technologies, we’ve created predictive in vitro models that offer targeted solutions to your complex problems. Our tissue model platforms, including retina, kidney and lung, reliably and accurately mimic in vivo physiology to take the guesswork out of drug development – providing answers to your questions and a window into the future of your therapy. Our intelligent preclinical models provide the reliable data you need to identify, avoid and mitigate risks and failures. By better understanding how your therapy will interact in vivo, you can make assured decisions to reduce drug attrition and give your safe and efficacious asset the best chance of reaching patients. In a nutshell, we help you save money, save time and save lives by getting ahead of the game.

When a five-year-old boy was blinded after a regular eye exam failed to spot a retinal detachment, his father made it his life's work to help eye care professionals by revolutionising retinal imaging. Optos was founded by Douglas Anderson with the goal to make a patient-friendly device to capture a digital ultra-widefield image of the retina. Today, millions of patients around the world have benefited from optomap® retinal imaging. You will find optomap systems in many independent High Street optometrists, as well as eye clinics at Great Ormond Street Hospital in London and Harvard Medical Center in Massachusetts. Our core products produce high resolution optomap images of 82% or 200◦ of the retina, something no other imaging device is capable of in a single comfortable capture. The most recent innovation from Optos integrates ultra-widefield retinal imaging and image-guided Optical Coherence Tomography (OCT). This combined device facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. More than 1,000 published and ongoing clinical trials as well as thousands of case studies and testimonials show the long-term value of optomap imaging and OCT in diagnosis, treatment planning, and patient engagement. As a division of Nikon Co. Ltd, Japan since 2015, Optos is approaching its 30th anniversary and proud to be recognized as a leading provider of devices to eye care professionals to provide a more complete approach to patient care.

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company's patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer's and other neurodegenerative diseases.

Perceptive Inc. is a global technology-enabled service provider dedicated to the biopharmaceutical industry. Recently rebranded as "Perceptive," the company focuses on advancing life-changing treatments through innovative services and solutions. Perceptive offers a range of services, including Perceptive Discovery, which aids in preclinical and first-in-human imaging to identify promising compounds. The Perceptive eClinical division enhances patient and clinical supply management, featuring services like Randomization & Trial Supply Management and Interactive Response Technology. Additionally, Perceptive Imaging provides expertise in scientific, regulatory, and operational aspects to support efficient data collection in clinical trials. With a client base that includes many leading pharmaceutical and biotech companies, Perceptive operates globally, ensuring smooth execution of clinical trials across various regions. The company has played a significant role in supporting nearly 12,000 clinical research trials and over 800 approvals, particularly in oncology and neuroscience, while upholding values of customer-centricity, quality, and accountability.